Bortezomib-Based Regimens Used As Induction In Newly Diagnosed Multiple Myeloma (Ndmm) Patients Eligible For Stem Cell Transplantation (Sct)The Cost-Utility Analysis
Abstract
Authors
J Mucha J Walczak K Tronczynski I Skrzekowska-Baran